

• Full Name:

Hyun Cheol Chung, MD, PhD

• Current Position & Affiliation:

**Professor Emeritus, Yonsei
University College of Medicine**

• Country: Korea**• Educational Background:**

1976-1982 MD Yonsei University College of Medicine

1985-1986 Rotatory Internship, Severance Hospital, Yonsei University College of Medicine

1986-1989 Resident, Internal Medicine, Severance Hospital,

1986-1992 PhD Yonsei University College of Medicine

• Professional Experience:

1994-1998 Assistant Professor, Medical Oncology, Yonsei Cancer Center, Yonsei University

1999-2003 Associate Professor, Medical Oncology, Yonsei Cancer Center, Yonsei University

2004-2021 Professor, Medical Oncology, Yonsei Cancer Center, Yonsei University

2005-2008 Chairman, Medical Oncology, Yonsei Cancer Center, Yonsei University

2009-2013 Director, Yonsei Cancer Center, Yonsei University College of Medicine

2013-2021 Director, Yonsei Song-dang Institute for Cancer Research

2021- Professor Emeritus, Medical Oncology, Yonsei University College of Medicine

• Professional Organizations:

2008-2009 President, Korean Cancer Study Group

2014-2015 Chairman of Executive Board Members, Korean Society of Medical Oncology

2018-2020 Chairman of Executive Board Members, Korean Cancer Association

• Main Scientific Publications:

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.

Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia P, Chung HC.

Nature 600:727-730, 2021.

Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis. Park S, Nam CM, Kim SG, Mun JE, Rha SY, Chung HC. **Eur J Cancer. 144:49-60, 2021**

Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients.

Chung HC, Kang YK, Chen Z, Bai Y, Wan Ishak WZ, Shim BY, Park YL, Koo DH, Lu J, Xu J, Chon HJ, Bai LY, Zeng S, Yuan Y, Chen YY, Gu K, Zhong WY, Kuang S, Shih CS, Qin SK, Chung HC, et al.

Cancer. 128:995-1003, 2022.

A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. Lee CK, Rha SY, Kim HS, Jung M, Kang B, Che J, Kwon WS, Park S, Bae WK, Koo DH, Shin SJ, Kim H, Jeung HC, Zang DY, Lee SK, Nam CM, Chung HC.

Nat Commun. 13:6002, 2022